Arcturus Therapeutics Holdings (ARCT) EBIAT (2018 - 2025)
Historic EBIAT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.
- Arcturus Therapeutics Holdings' EBIAT fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 649.07%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
- Latest data reveals that Arcturus Therapeutics Holdings reported EBIAT of -$13.4 million as of Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
- Over the past 5 years, Arcturus Therapeutics Holdings' EBIAT peaked at $117.3 million during Q4 2022, and registered a low of -$56.3 million during Q1 2021.
- Over the past 5 years, Arcturus Therapeutics Holdings' median EBIAT value was -$21.6 million (recorded in 2022), while the average stood at -$18.0 million.
- As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBIAT crashed by 47631.18% in 2021, and later soared by 40351.24% in 2022.
- Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBIAT stood at -$38.7 million in 2021, then skyrocketed by 403.51% to $117.3 million in 2022, then tumbled by 109.98% to -$11.7 million in 2023, then crashed by 156.3% to -$30.0 million in 2024, then skyrocketed by 55.18% to -$13.4 million in 2025.
- Its EBIAT was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.